- Home
- PNI vs ASRT Comparison
PNI vs ASRT Comparison
Compare PNI & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNI | ASRT |
|---|---|---|
| Founded | 2002 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.1M | 76.0M |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | PNI | ASRT |
|---|---|---|
| Price | $7.01 | $11.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 65.2K | 32.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.76% | N/A |
| EPS Growth | N/A | ★ 95.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,961,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.43 | $0.51 |
| 52 Week High | $7.35 | $12.95 |
Technical Indicators
Market Signals| Indicator | PNI | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 54.12 |
| Support Level | $6.86 | $0.67 |
| Resistance Level | $7.07 | $12.75 |
| Average True Range (ATR) | 0.06 | 0.47 |
| MACD | -0.02 | -0.17 |
| Stochastic Oscillator | 9.09 | 53.85 |
Price Performance
Historical ComparisonAbout PNI Pimco New York Municipal Income Fund II of Beneficial Interest
PIMCO New York Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State and New York City income tax. The fund portfolio of investments consists of investments in different sectors such as education, transportation, healthcare, and others.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.